Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Prediagnostic Blood Measurements.
Karl Smith-ByrneAgustin CeraniFlorence GuidaSirui ZhouAntonio AgudoKrasimira AleksandrovaAurelio Barricarte-GurreaMiguel Rodríguez BarrancoChristoph H BorchersInger Torhild GramJun HanChristopher Ian AmosRayjean J HungKjell GrankvistTherese Haugdhal NøstLiher ImazMaria Dolores ChirlaqueMikael JohanssonRudolf KaaksTilman KühnRichard M MartinJames D McKayValeria Maria PalaHilary A RobbinsTorkjel M SandangerDavid SchibliMatthias Bernd SchulzeRuth C TravisPaolo VineisElisabete WeiderpassPaul J BrennanMattias J JohanssonJohn Brent RichardsPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)
Our results find compelling evidence in favor of a protective role for a circulating metabolite, IVC, in lung cancer etiology. From the treatment of a Mendelian disease, isovaleric acidemia, we know that circulating IVC is modifiable through a restricted protein diet or glycine and L-carnatine supplementation. IVC may represent a modifiable and inversely associated biomarker for lung cancer.
Keyphrases